Descrizione del progetto
Un approccio innovativo fa avanzare il processo di sviluppo dei farmaci
Per il trattamento di varie malattie stanno emergendo nuovi farmaci a base di proteine e soprattutto di anticorpi. Date le dimensioni, l’eterogeneità e la complessità delle molecole proteiche, la loro caratterizzazione dettagliata e l’analisi della purezza in una pipeline di scoperta di farmaci si sono dimostrate impegnative dal punto di vista tecnologico. Gli scienziati del progetto LCxLCProt, finanziato dall’UE, propongono l’elaborazione di un metodo basato sulla cromatografia per caratterizzare i biofarmaci proteici. Questo nuovo metodo è adatto all’uso nella fase iniziale dello sviluppo dei farmaci e successivamente durante la produzione per scopi di controllo della qualità. Esso supporta le buone pratiche di produzione e, di conseguenza, la fiducia dei consumatori nei prodotti farmaceutici.
Obiettivo
Protein biopharmaceuticals, which globally represent about 20 % of the total pharmaceutical market, are becoming increasingly popular in the treatment of various diseases. Experts forecast that over 50 % of new drug approvals in the next decade will be for biologics, especially monoclonal antibodies. Very accurate structural characterization and purity analysis is required during both the development of the new drugs, and later during manufacturing for quality control purposes. Biopharmaceutical protein molecules are very large and heterogeneous, which makes their characterization very difficult. The goal of this project is to develop novel methods for the characterization of protein biopharmaceuticals at the protein level based on comprehensive two-dimensional liquid chromatography (LC×LC). Two approaches will be explored: the use of reversed phase separation mechanism in both dimensions with parallel gradients, and application of thermally responsive stationary phases for thermal modulation of LC×LC fractions. Parallel gradients provide the greatest orthogonality when the separation mechanisms in both dimensions are correlated, and allow the use of short modulation periods, which together lead to a dramatic increase in peak capacity (as demonstrated in preliminary experiments). Thermally responsive stationary phases allow trapping of the analyte bands at elevated temperatures, and their release at low temperature. This is compatible with intact protein analysis, especially when ion exchange is used in the first dimension of the LC×LC system. It is expected that the research will result in new, cutting edge methods for the analysis and characterization of protein biopharmaceuticals that will be applicable under the good manufacturing practice (GMP) conditions, improving the quality assurance/quality control and increasing the confidence in the pharmaceuticals.
Campo scientifico
Programma(i)
Argomento(i)
Meccanismo di finanziamento
MSCA-IF-EF-ST - Standard EFCoordinatore
9000 Gent
Belgio